

## Supporting Information

### **Benzoxaboroles: new potent inhibitors of the carbonic anhydrases of the pathogenic bacterium *Vibrio cholerae*.**

Alessandro Bonardi, Alessio Nocentini, Roberta Cadoni, Sonia del Prete, Pascal Dumy, Clemente Capasso, Paola Gratteri, Claudiu T. Supuran and Jean-Yves Winum

Sequence alignment of VchCA $\alpha$ , VchCA $\beta$ and VchCA $\gamma$	S2
Structural parameters of homology-built model of VchCA $\alpha$ , VchCA $\beta$ and VchCA $\gamma$ .	S5
Supplemental modeling figures	S10

		10	20	30	40	50	60
VchCA $\alpha$	1	.... ....	.... ....	.... ....	.... ....	.... ....	.... ....
5HPJ	22	-----	-----	-EWSYTGEHG	TEHWGDSFAT	CAEGVNQTPI	DINQTTQ AEL
		70	80	90	100	110	120
VchCA $\alpha$	61	.... ....	.... ....	.... ....	.... ....	.... ....	.... ....
5HPJ	61	QPF T L N Y Q G Q	V V G L L N N G H T	L Q A I V S G N N P	L Q I D G K T F Q L	P E H W G K V A P L	C A E G K N Q S P I
		130	140	150	160	170	180
VchCA $\alpha$	121	.... ....	.... ....	.... ....	.... ....	.... ....	.... ....
5HPJ	121	D V S Q S V E A D L	Q P F T L N Y Q G Q	V V G L L N N G H T	L Q A I V S G N N P	L Q I D G K T F Q L	K Q F H F H T P S E
		190	200	210	220	230	240
VchCA $\alpha$	181	.... ....	.... ....	.... ....	.... ....	.... ....	.... ....
5HPJ	181	N L L K G K Q F P L	E A H F V H A D E Q	G N L A V V A V M Y	Q V G S - E N P L L	K A L T A D M P T K	G N S T Q L T Q G I
		250	260	270	280	290	300
VchCA $\alpha$	241	.... ....	.... ....	.... ....	.... ....	.... ....	.... ....
5HPJ		P L A D W I P E S K	H Y Y R F N G S L T	T P P C S E G V R W	I V L K E P A H V S	N Q Q E Q Q L S A V	M G H N N R P V Q P
		310					
VchCA $\alpha$	301	.... ....					
5HPJ		H N A R L V L Q A D					



**Figure S1.** Sequence alignment of VchCA $\alpha$  with the template  $\alpha$ -CA from *Photobacterium profundum* (pdb 5HPJ).

		10	20	30	40	50	60
		.... ....	.... ....	.... ....	.... ....	.... ....	.... ....
VchCA $\beta$ _A	1	MPEIKQLFEN	NSKWSESIKA	ETPEYFAKLA	KGQNPDLWI	GCADSRVPAE	RLTGLYSGEL
VchCA $\beta$ _B	1	MPEIKQLFEN	NSKWSESIKA	ETPEYFAKLA	KGQNPDLWI	GCADSRVPAE	RLTGLYSGEL
6D2N	3	--ALQQLFEN	NVRWAEAIKQ	EDPDFFAKLA	RQQTPEYLWI	GCSDARVPAN	EIVGMLPGDL
		70	80	90	100	110	120
		.... ....	.... ....	.... ....	.... ....	.... ....	.... ....
VchCA $\beta$ _A	61	FVHRNVANQV	IHTDLNCLSV	VQYAVDVLQV	KHIIVCGHYG	CGGVTAIDN	PQLGLINNWL
VchCA $\beta$ _B	61	FVHRNVANQV	IHTDLNCLSV	VQYAVDVLQV	KHIIVCGHYG	CGGVTAIDN	PQLGLINNWL
6D2N	61	FVHRNVANVV	LHTDLNCLSV	IQFAVDVLKV	KHILVTGHYG	CGGVRASLHN	DQLGLIDGWL
		130	140	150	160	170	180
		.... ....	.... ....	.... ....	.... ....	.... ....	.... ....
VchCA $\beta$ _A	121	LHIRDYLLKH	REYLDQMPAE	D-RSDKLAEI	NVAEQVYNLA	NSTVLQNAWE	RGQAVEVHGF
VchCA $\beta$ _B	121	LHIRDYLLKH	REYLDQMPAE	D-RSDKLAEI	NVAEQVYNLA	NSTVLQNAWE	RGQAVEVHGF
6D2N	121	RSIRDLAYEY	REHLEQLPTE	EERVDRLCEL	NVIQQVANVS	HTSIVQNAWH	RGQSLSVHGC
		190	200	210	220		
		.... ....	.... ....	.... ....	.... ....	...	
VchCA $\beta$ _A	180	VYGIEDGRLE	YLGVRASRS	AVEDNYHKAL	EKIILNPNHRL	LCR	
VchCA $\beta$ _B	180	VYGIEDGRLE	YLGVRASRS	AVEDNYHKAL	EKIILNPNHRL	LCR	
6D2N	181	IYGIKDGLWKNL	NVTVSG---	-----L	DQLP-PQYRL	SPL	


**Figure S2.** Sequence alignment of type-I VchCA $\beta$  with the template type-I  $\beta$ -CA from *Pseudomonas aeruginosa* (pdb 6D2N).

		10	20	30	40	50	60
		.... ....	.... ....	.... ....	.... ....	.... ....	.... ....
VchCA $\gamma$ _A	1	SSIRSYKGIV	PKLGEGVYVD	SSAVLVGDIE	LGDDASIWPL	VAARGDVNHI	RIGKRTNIQD
VchCA $\gamma$ _B	1	SSIRSYKGIV	PKLGEGVYVD	SSAVLVGDIE	LGDDASIWPL	VAARGDVNHI	RIGKRTNIQD
VchCA $\gamma$ _C	1	SSIRSYKGIV	PKLGEGVYVD	SSAVLVGDIE	LGDDASIWPL	VAARGDVNHI	RIGKRTNIQD
3TIO	1	DVLHPYRDLF	PQIGQRMID	DSSVIGDVR	LADDVGIWPL	VVIRGDVHYV	QIGARTNIQD
		70	80	90	100	110	120
		.... ....	.... ....	.... ....	.... ....	.... ....	.... ....
VchCA $\gamma$ _A	61	GSVLHVTHKN	AENPNGYPLC	IGDDVTIGHK	VMLHGCTIHD	RVLVGMGSIV	LDGAVIENDV
VchCA $\gamma$ _B	61	GSVLHVTHKN	AENPNGYPLC	IGDDVTIGHK	VMLHGCTIHD	RVLVGMGSIV	LDGAVIENDV
VchCA $\gamma$ _C	61	GSVLHVTHKN	AENPNGYPLC	IGDDVTIGHK	VMLHGCTIHD	RVLVGMGSIV	LDGAVIENDV
3TIO	61	GSMLHVTHKS	SYNPDGNPLT	IGEDVTVGHK	VMLHGCTIGN	RVLVGMGSIL	LDGAIVEDDV
		130	140	150	160	170	180
		.... ....	.... ....	.... ....	.... ....	.... ....	.... ....
VchCA $\gamma$ _A	121	MIGAGSLVPP	GKRLESGFLY	MGSPVKQARP	LSDKERAFLV	KSSSNYVQSK	NDYLNDVKTV
VchCA $\gamma$ _B	121	MIGAGSLVPP	GKRLESGFLY	MGSPVKQARP	LSDKERAFLV	KSSSNYVQSK	NDYLNDVKTV
VchCA $\gamma$ _C	121	MIGAGSLVPP	GKRLESGFLY	MGSPVKQARP	LSDKERAFLV	KSSSNYVQSK	NDYLNDVKTV
3TIO	121	MIGAGSLVPQ	NKRLESGYLY	LGSPVKQIRP	LSDEEKAGLR	YSANNYVKWK	DEYL-----
		..					
VchCA $\gamma$ _A	181	RE					
VchCA $\gamma$ _B	181	RE					
VchCA $\gamma$ _C	181	RE					
3TIO		--					

**Figure S3.** Sequence alignment of VchCA $\gamma$  with the template  $\gamma$ -CA from *Escherichia coli* (pdb 3TIO).




**Figure S4.** 3D representation of the homology model of VchCA $\alpha$  and related parameters calculated with Swiss model.




**Figure S5.** Ramachandran Plot of 5HPJ (template) and VchCA $\alpha$  (HM).

**Table S1.** Structural parameters of 5HPJ (template) and VchCA $\alpha$  (HM).

	<b>5HPJ</b>	<b>VchCA<math>\alpha</math></b>
<b>MolProbity score</b>	1.09	1.25
<b>Clash score</b>	2.96	0.90
<b>Ramachandran Favoured</b>	98.14 %	92.13 %
<b>Ramachandran Outliers</b>	0.00 %	0.46 %
<b>Rotamer Outliers</b>	0.53 %	0.00 %
<b>C-Beta Deviations</b>	0	0
<b>Bad Bonds</b>	0/1768	0/1748
<b>Bad Angles</b>	1/2415	23/2385
<b>Cis Prolines</b>	3/13	4/16
<b>QMEAN</b>	0.46	-0.02
<b>C<math>\beta</math></b>	-0.37	0.44
<b>All Atom</b>	0.47	-1.12
<b>solvation</b>	-0.65	-1.44
<b>torsion</b>	0.81	-0.41



**Figure S6.** 3D representation of the homology model of type I VchCA $\beta$  and related parameters calculated with Swiss model.




**Figure S7.** Ramachandran Plot of 6D2N (template) and VchCA $\beta$  (HM).


**Table S2.** Structural parameters of 6D2N (template) and VchCA $\beta$  (HM).

	<b>6D2N</b>	<b>VchCA<math>\beta</math></b>
<b>MolProbity score</b>	1.60	1.78
<b>Clash score</b>	3.95	1.99
<b>Ramachandran Favoured</b>	97.10 %	93.41 %
<b>Ramachandran Outliers</b>	0.97 %	0.00 %
<b>Rotamer Outliers</b>	2.21 %	3.16 %
<b>C-Beta Deviations</b>	0	0
<b>Bad Bonds</b>	0/3390	0/3634
<b>Bad Angles</b>	2/4630	38/4934
<b>QMEAN</b>	-0.34	-0.65
<b>C<math>\beta</math></b>	0.06	0.21
<b>All Atom</b>	0.89	-0.66
<b>solvation</b>	0.41	-0.42
<b>torsion</b>	-0.56	-2.24





**Figure S8.** 3D representation of the homology model of VchCAy and related parameters calculated with Swiss model.






**Figure S9.** Ramachandran Plot of 3TIO (template) and VchCAy (HM).




**Table S3.** Structural parameters of 6D2N (template) and VchCAy (HM).


	<b>3TIO</b>	<b>VchCAy</b>
<b>MolProbity score</b>	1.70	1.11
<b>Clash score</b>	7.28	0.25
<b>Ramachandran Favoured</b>	97.68 %	95.96 %
<b>Ramachandran Outliers</b>	0.00 %	0.19 %
<b>Rotamer Outliers</b>	2.00 %	2.05 %
<b>C-Beta Deviations</b>	0	3
<b>Bad Bonds</b>	0/8280	0/4024
<b>Bad Angles</b>	1/11244	46/5449
<b>Cis Prolines</b>	6/47	3/24
<b>QMEAN</b>	1.01	-0.19
<b>C<math>\beta</math></b>	-1.49	-2.67
<b>All Atom</b>	-0.14	-0.51
<b>solvation</b>	0.38	-0.71
<b>torsion</b>	1.11	0.50




**Figure S10.** Ligand and protein RMSD (Å) vs time (100 ns) for the MD of the binding poses of benzoxaboroles **1** (t and p), and **10** with VchCA $\alpha$ .



**Figure S11.** Ligand and protein RMSD (Å) vs time (100 ns) for the MD of the binding poses of benzoxaboroles **1** (t) and **18** with VchCAβ.



**Figure S12.** Ligand and protein RMSD (Å) vs time (100 ns) for the MD of the binding poses of benzoxaboroles **1** (**p1** and **p2**), and **20** with VchCA $\gamma$ .



**Figure S13.** (A) Upper and (B) transversal and (C) surface view of VchCAy in adduct with superimposed **p1** and **p2** orientations of compound **1**.

## Materials and Methods

### *Chemistry*

Benzoxaborole **1** and tavaborole were commercially available. Compounds **2–23** were previously reported by this group [*Chem. Commun.* **2016**, 52(80), 11983-11986.]

### *Carbonic anhydrase assays*

An Sx.18Mv-R Applied Photophysics (Oxford, UK) stopped-flow instrument has been used to assay the catalytic activity of various CA isozymes for CO<sub>2</sub> hydration reaction [*J. Biol. Chem.* 1971, 246, 2561]. Phenol red (at a concentration of 0.2 mM) was used as indicator, working at the absorbance maximum of 557 nm, with 20 mM Tris (pH 7.4 for VchCA $\alpha$  and hCA II and 8.3 for VchCA $\beta$  and VchCA $\gamma$ ) as buffer, and 20 mM NaClO<sub>4</sub> (for maintaining constant the ionic strength), following the initial rates of the CA-catalyzed CO<sub>2</sub> hydration reaction for a period of 10–100 s. The CO<sub>2</sub> concentration ranged from 1.7 to 17 mM for the determination of the kinetic parameters and inhibition constants. For each inhibitor, at least six traces of the initial 5–10% of the reaction have been used for determining the initial velocity. The uncatalyzed rates were determined in the same manner and subtracted from the total observed rates. Stock solutions of inhibitor (0.1 mM) were prepared in distilled-deionized water and dilutions up to 0.01 nM were done thereafter with the assay buffer. Inhibitor and enzyme solutions were preincubated together for 30 min at room temperature prior to assay, in order to allow for the formation of the E–I complex. The inhibition constants were obtained by nonlinear least-squares methods using PRISM 3 and the Cheng-Prusoff equation, as reported earlier, and represent the mean from at least three different determinations [*Bioorg. Chem.* 2019, 93, 103336; *J. Enzyme Inhib. Med. Chem.* 2020, 35, 59-64; *J. Enzyme Inhib. Med. Chem.* 2019, 34(1), 510-518.]. VchCA $\alpha$ , VchCA $\beta$ , and VchCA $\gamma$  were recombinant proteins obtained in-house as reported earlier [*J. Enzyme Inhib. Med. Chem.* 2014, 29(1), 23-7.; *Bioorg. Med. Chem.* 2016, 24(5), 1115-20.; 11-15; *Acta Crystallogr. D Biol. Crystallogr.* 2015, 71(Pt 12), 2449-56.; *Bioorg. Med. Chem. Lett.* 2016, 26(8), 1941-6.; *Bioorg. Med. Chem.* 2016, 24(16), 3413-7.].

## Molecular Modelling

The primary sequences of VchCA $\alpha$ , VchCA $\beta$ , and VchCA $\gamma$  were retrieved from the UniProt Consortium. The crystal structure of  $\alpha$ -CA from *Photobacterium profundum* (PDB 5HPJ [PLoS One. 2016, 11, e0168022.]),  $\beta$ -CA from *Pseudomonas aeruginosa* (PDB 6D2N [ChemMedChem. 2018, 13, 2024-2029]), and  $\gamma$ -CA homologous protein from *Escherichia coli* (PDB 3TIO [Acta Crystallogr. D Biol Crystallogr. 2012, 68, 920-6.]) were used as templates in the homology modeling procedure. Multiple models were generated using the Prime module of Schrödinger [Prime, v.5.5] and the SwissModel platform (Nucleic Acids Res. 2018, 46, W296-W303) and submitted to loop refinements and quality evaluation procedures (Figures S4-S9 and Tables S1-S3, Supporting Information). The best scored structures of VchCA $\alpha$ , VchCA $\beta$  and the VchCA $\gamma$  crystal structure (retrieved as PDB 5CXK [Acta Crystallogr. D Biol. Crystallogr. 2015, 71(Pt 12), 2449-56.]) were prepared using the Protein Preparation Wizard tool implemented in the Schrödinger suite [Schrödinger Suite Release 2019-1, Schrödinger, LLC, New York, NY, 2019: (a) Prime, v.5.5; (b) Maestro v.11.9; (c) Epik, v.4.7; (d) Impact, v.8.2; (e) Macromodel v.12.3. (f) Glide, v.8.2]. The energy minimization protocol with a root mean square deviation (RMSD) value of 0.30 Å was applied using force field OPLS3e. The ligand structures in the B(OH) $_2^-$  form were submitted to QM geometry optimization (B3LYP/6-31G $^{*+}$ ) and ESP charges calculation with the Jaguar module (v.10.3) of Schrödinger. The software Glide was used for docking [Glide, v.8.2]. Grids were centered on the centroids of the zinc-coordinating residues and ligands were docked using QM-computed charges and the standard precision mode (SP). The best poses for each compound were re-docked and scored for its binding free energies by the Prime MM-GBSA protocol [Prime, v.5.5], using QM charges and a VSGB solvation model. Additionally, they were submitted to a MD simulation using Desmond [Desmond v.5.7] and the OPL3e force field. Specifically, the system was solvated in an orthorhombic box using TIP4PEW water molecules, extended 15 Å away from any protein atom. It was neutralized adding chlorine and sodium ions. The simulation protocol included a starting relaxation step followed by a final production phase of 100 ns. In particular, the relaxation step comprised the following: (a) a stage of 100 ps at 10 K retaining the harmonic restraints on the solute heavy atoms (force constant of 50.0 kcal mol $^{-1}$  Å $^{-2}$ ) using the NPT ensemble with Brownian dynamics; (b) a stage of



12 ps at 10 K with harmonic restraints on the solute heavy atoms (force constant of 50.0 kcal mol<sup>-1</sup> Å<sup>-2</sup>), using the NVT ensemble and Berendsen thermostat; (c) a stage of 12 ps at 10 K and 1 atm, retaining the harmonic restraints and using the NPT ensemble and Berendsen thermostat and barostat; (f) a stage of 12 ps at 300 K and 1 atm, retaining the harmonic restraints and using the NPT ensemble and Berendsen thermostat and barostat; (g) a final 24 ps stage at 300 K and 1 atm without harmonic restraints, using the NPT Berendsen thermostat and barostat. The final production phase of MD was run using a canonical NPT Berendsen ensemble at temperature 300 K. During the MD simulation, a time step of 2 fs was used while constraining the bond lengths of hydrogen atoms with the M-SHAKE algorithm. The atomic coordinates of the system were saved every 100 ps along the MD trajectory. Protein and ligand RMSD, ligand torsions evolution and occupancy of intermolecular hydrogen bonds and hydrophobic contacts were computed along the production phase of the MD simulation with the Simulation Interaction Diagram tools implemented in Maestro.